» Articles » PMID: 23271822

High-flow Oxygen Administration by Nasal Cannula for Adult and Perinatal Patients

Overview
Journal Respir Care
Publisher Mary Ann Liebert
Specialty Pulmonary Medicine
Date 2012 Dec 29
PMID 23271822
Citations 62
Authors
Affiliations
Soon will be listed here.
Abstract

The nasal cannula has been a commonly used patient interface to provide supplemental oxygen since its introduction in the 1940s. Traditionally, it has been categorized as a low-flow device and capable of delivering a 0.4 F(IO(2)) with flows up to 6 L/min to adults with normal minute ventilation. However, there is considerable performance variability among patients and design, which results in an exponential decline in delivered F(IO(2)) as breathing frequencies increase. The nasal cannula has also been successfully adapted for use in perinatal and pediatric respiratory care; flows are reduced, in the range of 0.25-1 L/min, due to smaller minute volumes. A decade or so ago, high-flow nasal cannula (HFNC) oxygen therapy was introduced, accompanied by heated humidification systems to prevent the associated drying of upper airway mucosa and to increase patient comfort. Therapeutic flows for adults were in the 15-40 L/min range; F(IO(2)) could be independently adjusted with air/O(2) blending. The HFNC has also found additional clinical application in perinatal care, as delivery systems with flows > 2 L/min could create a distending pressure similar to nasal CPAP. There is a small but growing body of information from clinical trials that supports use of HFNC as an alternative oxygen interface for adults who present with moderate hypoxemia that persists after receiving oxygen by reservoir-bag masks or similar therapy. Clinical observations report greater patient acceptance and comfort versus oxygen masks. HFNC therapy has also been considered valuable in perinatal care in treating the respiratory distress syndrome or supporting patients after extubation similar to nasal CPAP. At present, research-based evidence for the role of HFNC for its perinatal applications remains unclear. This review will identify proposed mechanisms for therapeutic effectiveness, current delivery equipment, guidelines for rational patient application, and direction for further research.

Citing Articles

Adherence and influencing factors of high-flow nasal cannula humidified oxygen therapy in elderly patients with stable chronic obstructive pulmonary disease: A meta-analysis.

Yang Y, Liu T, Li D, Ren X, Luo Z, Chen X Ann Thorac Med. 2025; 20(1):49-55.

PMID: 39926398 PMC: 11804951. DOI: 10.4103/atm.atm_151_24.


A Comprehensive Review on High-Flow Nasal Cannula Oxygen Therapy in Critical Care: Evidence-Based Insights and Future Directions.

Petkar S, Wanjari D, Priya V Cureus. 2024; 16(8):e66264.

PMID: 39238720 PMC: 11375959. DOI: 10.7759/cureus.66264.


Use of High-Flow Nasal Cannulas in Saudi's Neonatal Level III Intensive Care Units: A Nationwide Questionnaire Study.

Algarni S, Alshammari K, Alkhalifah M, Almutairi W, Aljaidi A, Alruwaili A Glob Pediatr Health. 2024; 11:2333794X241258142.

PMID: 38846062 PMC: 11155366. DOI: 10.1177/2333794X241258142.


Apnoeic oxygenation with high flow nasal oxygen for interventional surgery of the larynx and pharynx.

Langer C, Wittekindt C, Arens C, Kabisch S Eur Arch Otorhinolaryngol. 2024; 281(9):4889-4895.

PMID: 38750174 PMC: 11392969. DOI: 10.1007/s00405-024-08726-6.


Proposed protocol for utilising high-flow nasal oxygen therapy in treatment of dogs hospitalised due to pneumonia.

Teppo A, Rossi H, Rajamaki M, Hyytiainen H BMC Vet Res. 2023; 19(1):167.

PMID: 37735404 PMC: 10512590. DOI: 10.1186/s12917-023-03737-7.